Basal insulin therapy

Current Diabetes Reports

Volumn 4, Issue 5, 2004, Pages 342-345

  Clore, John N ^a   Thurby Hay, Linda ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; PREDNISONE;

ASTHMA; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; OSTEOARTHRITIS; REVIEW; SIDE EFFECT;

EID: 8344231549     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0035-3     Document Type: Review

References (24)

1. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS)Group [no authors listed]. Lancet 1998, 352: 37-853.
2. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854-865.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
4. Polonsky KS, Licinio-Paixao J, Given BD, et al.: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986, 77:98-105.
5. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992, 15: 18-368.
6. Boden G, Cheung P, Homko C: Effects of acute insulin excess and deficiency on gluconeogenesis and glycogenolysis in type 1 diabetes. Diabetes 2003, 52:133-137.
7. Rebrin K, Steil GM, Getty L, Bergman RN: Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995, 44:1038-1045.
8. Clore JN, Glickman PS, Nestler JE, Blackard WG: In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans. Am J Physiol 1991, 261:E425-E429.
9. Boden G: Effects of free fatty acids on gluconeogenesis and glycogenolysis. Life Sci 2003, 72:977-988.
10. Boden G, Chen X, Capulong E, Mozzoli M: Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 2001, 50:810-816.
11. Clore JN, Allred J, White D, et al.: The role of plasma fatty acid composition in endogenous glucose production in patients with type 2 diabetes mellitus. Metab Clin Exp 2002, 51:1471-1477.
12. Blackard WG, Clore JN: Insulin effects on substrate metabolism. In Clinical Research in Diabetes and Obesity. Edited by Draznin B, Rizza R. Totowa, NJ: Humana Press; 1997:205-220.
13. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA: Effect of free fatty acids on glucose production and utilization in man. J Clin Invest 1983, 72:1737-1747.
14. Buse JB: Should postprandial glucose be routinely measured and treated to a particular target? No! Diabetes Care 2003, 26:1615-1618.
15. Riddle MC: Evening insulin strategy. Diabetes Care 1990, 13:676-686.
16. Perriello G, De F, Torlone E, et al.: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 1990, 33:52-59.
17. Clore JN, Nestler JE, Blackard WG: Sleep-associated fall in glucose disposal and hepatic glucose output in normal humans. Putative signaling mechanism linking peripheral and hepatic events. Diabetes 1989, 38:285-290.
18. Lepore M, Pampanelli S, Fanelli C, et al.: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
19. Yki-Jarvinen H, Ryysy L, Nikkila K, et al.: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999, 130:389-396.
20. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26: 080-3086.
21. Schober E, Schoenle E, Van D, Wernicke-Panten K: Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15:369-376.
22. Home P, Bartley P, Russell-Jones D, et al.: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004, 27:1081-1087.
23. Hamann A, Matthaei S, Rosak C, Silvestre L: A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003, 26:1738-1744.
24. Queale WS, Seidler AJ, Brancati FL: Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997, 157:545-552.